Corbus Pharmaceuticals | Evaluate

Smaller companies set for third-quarter catalysts

The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.

Second-quarter catalysts for the smaller players

Key catalysts approach for Orphazyme, Gemini and Immutep.

September 11, 2020

A rare yet early-stage win for Galapagos and Gilead in scleroderma

September 08, 2020

Corbus keeps searching for a lenabasum signal

June 26, 2020

Rare diseases dominate catalysts for the smallest companies

Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.

August 31, 2018

After Astra’s failure lupus attention turns to Aurinia

November 18, 2016

Snippet roundup: A hit for St. Jude, a knockback for Dynavax and dubious data for Corbus

November 11, 2016

Upcoming events – Corbus leans on Resunab and crunch time for Aeterna’s Macrilen